ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

2025 HFSA CME Symposium - Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in Patients with Heart Failure: New Opportunities to Improve Patient Outcomes

By: PRLog
This CME Symposium takes place on Sunday, September 28, 2025, from 5:30PM - 6:45PM CT during the 2025 Annual Scientific Meeting of the Heart Failure Society of America at the Hilton Minneapolis in Minneapolis, Minnesota.

HAZLET, N.J. - Aug. 19, 2025 - PRLog -- In this symposium, Chair Dr. Mathew Maurer, and faculty members Dr. Noel Dasgupta, Dr. Omar Abou Ezzeddine, and Dr. Frederick Ruberg, will explain best practices for screening and diagnosing ATTR-CM in patients with concomitant HF, describe the treatment landscape, and, through case presentation, discuss practical considerations in management.

Click here for more information

CHAIR

Mathew Maurer, MD

Arnold and Arlene Goldstein Professor of Cardiology
Professor of Medicine
Columbia University Irving Medical Center
Vagelos College of Physicians & Surgeons
New York, New York

FACULTY

Noel Dasgupta, MD

Associate Professor of Clinical Medicine and
Pathology & Laboratory Medicine
Indiana University School of Medicine
Indianapolis, Indiana

Omar Abou Ezzeddine, MD, MS
Associate Professor of Medicine
Mayo Clinic College of Medicine and Science
Rochester, Minnesota

Frederick Ruberg, MD
Chief of Cardiovascular Medicine
Boston Medical Center
Thomas J. Ryan Professor of Cardiovascular Medicine
Boston University Chobanian & Avedisian School of Medicine
Boston, Massachusetts

Educational Objectives
  • Identify red flags which raise suspicion for ATTR-CM in HF patients
  • Discuss the diagnostic tests to quickly and accurately diagnose ATTR-CM
  • Explain the evidence and effectiveness of traditional HF medications in patients with ATTR-CM
  • Summarize the evolving landscape for ATTR-CM therapies
  • Recognize how patient monitoring and assessment is constantly changing and improving
Target Audience
This educational activity is intended for clinicians who manage patients with heart failure.

Educational Grant
Voxmedia gratefully acknowledges the independent educational grant provided by Alnylam Pharmaceuticals, Inc.

Accreditation and Credit Designation Statements
Voxmedia, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Voxmedia, LLC designates this live activity for a maximum of 1.25 AMA PRA Category Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Nurse practitioners may participate in this educational activity and earn a certificate of completion as AANP accepts AMA PRA Category 1 Credits™ through its reciprocity agreements. The National Commission on Certification of Physician Assistants accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.

Contact
Voxmedia, LLC
***@voxmedia.us

Photos: (Click photo to enlarge)

Voxmedia Logo CME Program at the HFSA 2025 Annual Meeting


Source: CMEPlanet

Read Full Story - 2025 HFSA CME Symposium - Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in Patients with Heart Failure: New Opportunities to Improve Patient Outcomes | More news from this source

Press release distribution by PRLog
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.